Hepatitis E pathophysiology: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 14: Line 14:


===Transmission===
===Transmission===
The [[hepatitis E virus]] is transmitted mainly through the fecal-oral route, due to fecal contamination of drinking water.
Hepatitis E is mainly transmitted through the fecal-oral route. In developing countries this occurs mostly from the ingestion of contaminated water.<ref name="pmid22549046">{{cite journal| author=Kamar N, Bendall R, Legrand-Abravanel F, Xia NS, Ijaz S, Izopet J et al.| title=Hepatitis E. | journal=Lancet | year= 2012 | volume= 379 | issue= 9835 | pages= 2477-88 | pmid=22549046 | doi=10.1016/S0140-6736(11)61849-7 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22549046  }} </ref>
 
Other transmission routes have been identified, including:
Other transmission routes have been identified, including:
* Foodborne [[transmission]] from [[ingestion]] of products derived from [[infected]] animals
* Foodborne [[transmission]] from [[ingestion]] of products derived from [[infected]] animals
* [[Transfusion]] of infected [[blood]] products
* [[Transfusion]] of infected [[blood]] products
* Vertical [[transmission]] from a pregnant woman to her [[fetus]]
* Vertical [[transmission]] from a pregnant woman to the [[fetus]]
* [[Ingestion]] of raw or uncooked shellfish has also been identified as the source of sporadic cases in [[endemic]] areas.
* [[Ingestion]] of raw or uncooked shellfish has also been identified as the source of sporadic cases in [[endemic]] areas.
Although humans are considered the natural host for the [[hepatitis E virus]], [[antibodies]] to the [[hepatitis E virus]] or closely related [[viruses]] have been detected in primates and several other animal species, suggesting [[infection]] by the virus.
Hepatitis E is a waterborne disease. Contaminated water or food supplies have been implicated in major outbreaks.


==Associated Conditions==
==Associated Conditions==

Revision as of 12:41, 27 August 2014

Hepatitis E Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Epidemiology and Demographics

Risk Factors

Screening

Differentiating Hepatitis E from other Diseases

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Treatment

Medical Therapy

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Hepatitis E pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hepatitis E pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hepatitis E pathophysiology

CDC on Hepatitis E pathophysiology

Hepatitis E pathophysiology in the news

Blogs on Hepatitis E pathophysiology

Directions to Hospitals Treating Hepatitis E

Risk calculators and risk factors for Hepatitis E pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]

Overview

Pathogenesis

The cellular receptor for HEV and the mode of entry of the virus into the host cell are yet to be identified.[1] However, heparin sulfate proteoglycans are known to be required for the attachment to target cells and infection. A proposed theory for the replication of virus is that, once within the host cell, HEV exposes its RNA, which is then translated into proteins (ORF1) that will be responsible for the production of a negative-strand RNA. This newly produced strand will serve as a template for new genomic and subgeneric RNAs. The new RNAs, are translated to ORF2 and ORF3. The ORF proteins will then transport the RNA into new virions that will use cellular lipids and ORF3 for their formation.[2][3]

Similarly to other hepatitis viruses, HEV is not cytopathic. The host's immune response to the infection is the cause of liver injury.[2]

Although the pathogenesis behind the increased mortality of infected pregnant women is not completely understood, it is thought to be related to hepatocyte injury mediated by endotoxins, and greater T-cell type 2 response.[4]

Transmission

Hepatitis E is mainly transmitted through the fecal-oral route. In developing countries this occurs mostly from the ingestion of contaminated water.[5] Other transmission routes have been identified, including:

Associated Conditions

HIV Co-Infection

Organ Transplant Recipients

Gross Pathology

Microscopic Pathology

Patients who develop chronic liver disease often have changes in liver histology. These may include:[2]

In severe cases, these changes may evolve to fibrosis and cirrhosis.[2][6]

References

  1. Kalia M, Chandra V, Rahman SA, Sehgal D, Jameel S (2009). "Heparan sulfate proteoglycans are required for cellular binding of the hepatitis E virus ORF2 capsid protein and for viral infection". J Virol. 83 (24): 12714–24. doi:10.1128/JVI.00717-09. PMC 2786843. PMID 19812150.
  2. 2.0 2.1 2.2 2.3 Aggarwal R, Jameel S (2011). "Hepatitis E." Hepatology. 54 (6): 2218–26. doi:10.1002/hep.24674. PMID 21932388.
  3. Nagashima S, Takahashi M, Tanaka T, Yamada K, Nishizawa T; et al. (2011). "A PSAP motif in the ORF3 protein of hepatitis E virus is necessary for virion release from infected cells". J Gen Virol. 92 (Pt 2): 269–78. doi:10.1099/vir.0.025791-0. PMID 21068219.
  4. Pal R, Aggarwal R, Naik SR, Das V, Das S, Naik S (2005). "Immunological alterations in pregnant women with acute hepatitis E." J Gastroenterol Hepatol. 20 (7): 1094–101. doi:10.1111/j.1440-1746.2005.03875.x. PMID 15955220.
  5. Kamar N, Bendall R, Legrand-Abravanel F, Xia NS, Ijaz S, Izopet J; et al. (2012). "Hepatitis E." Lancet. 379 (9835): 2477–88. doi:10.1016/S0140-6736(11)61849-7. PMID 22549046.
  6. Gérolami R, Moal V, Colson P (2008). "Chronic hepatitis E with cirrhosis in a kidney-transplant recipient". N Engl J Med. 358 (8): 859–60. doi:10.1056/NEJMc0708687. PMID 18287615.

Template:WS Template:WH